4.5 Review

CD44 and HCELL: Preventing hematogenous metastasis at step 1

期刊

FEBS LETTERS
卷 585, 期 20, 页码 3148-3158

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.febslet.2011.07.039

关键词

CD44; Hematopoietic cell E-/L-selectin ligand; Metastasis; Glycosylation; Selectin

资金

  1. National Institutes of Health
  2. National Heart Lung Blood Institute
  3. National Cancer Institute [PO1 HL107146, RO1 HL60528, RO1 HL73714, RO1 CA121335]

向作者/读者索取更多资源

Despite great strides in our knowledge of the genetic and epigenetic changes underlying malignancy, we have limited information on the molecular basis of metastasis. Over 90% of cancer deaths are caused by spread of tumor cells from a primary site to distant organs and tissues, highlighting the pressing need to define the molecular effectors of cancer metastasis. Mounting evidence suggests that circulating tumor cells (CTCs) home to specific tissues by hijacking the normal leukocyte trafficking mechanisms. Cancer cells characteristically express CD44, and there is increasing evidence that hematopoietic cell E-/L-selectin ligand (HCELL), a sialofucosylated glycoform of CD44, serves as the major selectin ligand on cancer cells, allowing interaction of tumor cells with endothelium, leukocytes, and platelets. Here, we review the structural biology of CD44 and of HCELL, and present current data on the function of these molecules in mediating organ-specific homing/metastasis of CTCs. (C) 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据